Drug Used for Treatment of Anemia Flashcards

1
Q

what are 3 types of iron and vitamin deficiency anemias?

A

– Hypochromic, microcytic anemia (small red cells with low hemoglobin; caused by chronic blood loss giving rise to iron deficiency)
– Megaloblastic anemia (large red cells, few in number); caused by a deficiency of Vit B12 or folic acid
– Pernicious anemia (fewer normal-sized red cells, each with a normal hemoglobin content); caused by a deficiency of Vit B12 due to defect in intrinsic factor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what other blood cell deficiencies might there be?

A

– Erythrocytes, neutrophils and platelets

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

causes of anemia

which nutrients necessary for haemopoiesis might be deficient?

A

– iron
– folic acid and vitamin B 12
– pyridoxine (vit B6) and vitamin C (important for iron abs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

common causes of depression on bone marrow?

A

– drug toxicity (e.g. anticancer drugs, clozapine )
– exposure to radiation, including radiotherapy
– diseases of the bone marrow (e.g. idiopathic aplastic
anaemia, leukaemias)
– reduced production of, or responsiveness to, erythropoietin
(e.g. chronic renal failure, rheumatoid arthritis, AIDS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what other cause is ther for anemia?

A

Excessive destruction of red blood cells (i.e.
haemolytic anaemia)

  • EPO that synthesized RBCs, most synthesized in kidneys
  • Chronic renal failure - less synthesis of RBCs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what are 2 categories for treating anemia?

A

hematinic agents

hematopoietic growth factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

name 2 hematinic agents

A
  • Iron

- Folic acid and Vit B12

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

name 4 Hematopoietic Growth Factors

A
  • Erythropoietin
  • Granulocyte Colony-Stimulating Factor (G-CSF)
  • Granulocyte-Monocyte Colony-Stimulating Factor (GM-CSF)
  • Megakaryocyte (Thrombopoietic) Growth Factors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Hematinic agents: Iron

where is iron in the body?
normal daily requirement for men, growing children, menstruating womem?
pregnant women?

A

• The body of a 70 kg man contains about 4 g of iron
• 65% of which circulates in the blood as hemoglobin.
• About one-half of the remainder is stored in the liver,
spleen and bone marrow, as ferritin and hemosiderin .
• Normal daily requirement for iron is 5 mg for men, and 15 mg for growing children and for menstruating women
• A pregnant woman needs between 2 and 10 times this
amount because of the demands of the fetus.
• The average diet provides 15–20 mg of iron daily, mostly in meat.
• Iron in meat is generally present as heme, and about 20– 40% of hem iron is available for absorption.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Hematinic agents: Iron

how much is absorbed daily?
pathway?
how much is lost daily?

A

plasma iron goes to bone marrow in RBC precursors

  • 24mg go to Hb in RBC
  • 6mg go to mononuclear phagocytes (mnp) representing aborted cells that fail to develop into functional RBCs
  • 24 mg from Hb in rbc to stores in mnp
  • we lose 1-2 mg daily, maintain fixed amount
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Hematinic agents: Iron

which form of iron is absorbed?
where is it absorbed?
what is a transport protein for iron?

A

• Ferric iron (Fe3+) must be converted to ferrous iron (Fe2+, reduced form) for absorption (by ferric reductase enzyme) in the GI tract.
• Absorption involves active transport into mucosal cells in the duodenum and jejunum (the upper ileum), from where it can be transported into the plasma and/or stored intracellularly as ferritin.
• Total body iron is controlled exclusively by absorption; in iron deficiency, more is transported into plasma than is stored as ferritin in jejunal mucosa.
• Iron that is released is transported by transferrin (the
transport protein).
• Transferrin delivers the iron to either the liver for storage or to bone marrow for further hemoglobin and RBC production

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Hematinic agents: Iron

name oral and IV common drugs

A

Iron formulations are used for treatment of iron deficiency

Oral: ferrous sulfate, ferrous fumarate, ferrous gluconate, polysaccharide-iron complex
IV: iron dextran, sodium ferric gluconate, iron sucrose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Hematinic agents: Iron

iron formulations MOA

A

• Most iron is recycled through the body; RBCs contain the majority of iron in hemoglobin. Because the life span of an RBC is about 120 days, in 1 day about 0.8% of the RBCs are broken down, and their iron is recycled:
-Senescent (old) RBCs are taken up by the reticular system (spleen and macrophages) and are relieved of their iron

Lose 0.8% RBC everday - broken down and iron is released because of their lifespan

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Hematinic agents: Iron

Pharmacokinetics

what inhibits its absorption?

A
  • Ferrous iron (Fe2+) is better absorbed than ferric iron (Fe3+) and is absorbed in the duodenum. About 25% of ferrous iron is absorbed.
  • Iron from animals (heme iron) is ferrous; iron from vegetarian foods (nonheme iron) is ferric, and so a smaller percentage is available for absorption.
  • Iron should be taken on an empty stomach; many foods inhibit iron absorption. Other factors that markedly decrease absorption include antacids, H2 blockers, proton pump antagonists, and calcium supplements.
  • Most ingested iron either is not absorbed or is lost with the enterocytes when their turnover results in shedding into the lumen of the GI tract.
  • Some oral compounds are combined with ascorbic acid, which is designed to enhance absorption.
  • Vegetarians - iron supplements
    Nonheme iron for vegetarian foods
  • PPIs, H2RAs, calc supplement inhibit iron abs
  • tale orange juice, ascorbic acid enhances abs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Hematinic agents: Iron

clinical uses

A

• To treat iron deficiency anaemia, which can be
caused by:
• Chronic blood loss (e.g. with menorrhagia, hookworm, colon cancer)
• Increased demand (e.g. in pregnancy and early infancy)
• Inadequate dietary intake (uncommon in developed countries)
• Inadequate absorption (e.g. following gastrectomy, or in diseases such as celiac disease, where the intestinal mucosa is damaged by an immunologically based intolerance to the wheat protein gluten)
- more common in females with menstruation
celiac disease often accompanied with T1 Diabetes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Hematinic agents: Iron

side effects

A

• Gastrointestinal disturbances.
• Severe toxic effects occur if large doses are ingested;
such acute poisoning can be treated with desferrioxamine, an iron chelator as can chronic iron overload in diseases such as thalassemia.

17
Q

when does iron overload occur? (2)

A

Iron overload occurs in chronic hemolytic anaemias
requiring frequent blood transfusions, such as;
- Thalassaemias (a large group of genetic disorders of globin chain synthesis)
- Hemochromatosis (a genetic iron storage disease with increased iron absorption, resulting in damage to liver, islets of Langerhans, joints and skin).

18
Q

how to treat iron overload?

3

A
  • Desferrioxamine: form a complex with ferric iron which, unlike unbound iron, is excreted in the urine.
  • Desferrioxamine is not absorbed from the gut. Therefore, it must be given by slow SC infusion. For acute iron overdose, it is given IM or IV
  • Deferiprone is an orally absorbed iron chelator, used as an alternative treatment for iron overload in patients who are unable to take desferrioxamine.
  • Deferasirox is similar, but can cause GI bleeding
19
Q

Hematinic agents: Folic Acid and Vitamin B12

what is the role of folic acid and Vit B12

A

Prototype: B9: Folic acid; B12: Cyanocobalamin,
hydroxocobalamin
• Vitamin B12 and folic acid play key roles in DNA synthesis. Active forms of folic acid serve as enzyme cofactors that play key roles in the synthesis of purines and pyrimidines, as well as amino acids, in the body.
• A deficiency of folic acid or B12 affect cells that are actively dividing, such as the cells of the bone marrow, which are involved in erythropoiesis. Therefore, the deficiencies of these vitamins is anemia.
• Specifically, B12 deficiency results in abnormal DNA replication, which prevents cells from maturing properly, leading to production of large, dysfunctional RBC precursors (megaloblasts) that do not leave the marrow, or abnormal cells that do leave the marrow.
• B12 deficiency can also affect the nervous system, causing inflammation, demyelination, and neuronal cell death

20
Q

Hematinic agents: Folic Acid and Vitamin B12

MOA?

A
  • Folic acid: Reduction of folic acid, catalyzed by dihydrofolate reductase in two stages yields dihydrofolate (FH 2 ) and tetrahydrofolate (FH 4 ), co-factors which transfer methyl groups (1- carbon transfers) in several important metabolic pathways.
  • FH 4 is essential for DNA synthesis.
  • B12: involves conversion of both methyl-FH 4 to FH 4 and homocysteine to methionine

see diagram:

  • Convert homocysteine to methionine important for DNA synthesis B12 important for conversion of methyl tetrahydrofolate to and tetrahydrofolate (methyl FH4 tp FH4)
  • Thymidylate synthase convert methylene dUMP to dTMP or DNA synthesis
  • Reduction of folic acid yields dihydrofolate and tetrahydrofolate
21
Q

Hematinic agents: Folic Acid and Vitamin B12

indications for Vitamin B12

A
  • Pernicious anemia

* Megaloblastic and macrocytic anemias caused by poor B12 absorption

22
Q

Hematinic agents: Folic Acid and Vitamin B12

Folic Acid

A
  • Megaloblastic and macrocytic anemias
  • Prevention of neural tube defects in neonates (give to pregant women)
  • Adjunct to methotrexate to prevent methotrexate toxicity (can be used for alopecia)
  • Pernicious anemia (combined with B12)
23
Q

Hematopoietic Growth Factors: Erythropoietins

what are they?
what are 2 prototypes?

A

stimulate production of RBC’s
• Prototype: epoetin alfa (also known as recombinant human erythropoietin, rHuEPO or simply, EPO)
• Other: darbepoetin alfa (longer duration of action)

24
Q

Hematopoietic Growth Factors: Erythropoietins

MOA?

A

Erythropoietin is an endogenous protein that stimulates the production of RBCs (erythrocytes). Erythropoietin is typically released in response to
hypoxia and is largely synthesized in the kidneys, with a small amount coming from the liver

EPO 90% made in kidneys
10% liver
All goes into bone marrow to stimulate synth of RBCs

25
Q

Hematopoietic Growth Factors: Erythropoietins

MOA continued
where does EPO bind a receptor and what types of effects will happen

A
  • Patients with a deficiency of erythropoietin will be anemic. This occurs commonly in patients with renal failure.
  • Once released, erythropoietin binds to a receptor on the surface of committed erythroid progenitor cells in the bone marrow.
  • Binding to this receptor mediates a variety of intracellular effects through tyrosine kinases, including the inhibition of apoptosis.
  • Inhibiting apoptosis prevents RBCs from dying at an early stage of development. Erythropoietin also promotes proliferation through Janus protein kinase-2 (JAK2) pathways

More cell proliferation, no death of RBCs

26
Q

Hematopoietic Growth Factors: Erythropoietins

Pharmacokinetics

A
  • Epoetin alpha is administered parenterally by either the SC or the IV route. The elimination half-life of IV Epoetin alpha is approximately 4 to 8 hours.
  • Darbepoetin alfa is a modified form of erythropoietin, with amino acid mutations that have led to a prolonged elimination half-life of approximately 24 hours.
27
Q

Hematopoietic Growth Factors: Erythropoietins

Indications

A
  • Anemia
  • In advanced renal failure (can’t make it)
  • Associated with chemotherapy and acquired immunodeficiency syndrome (AIDS)
28
Q

Hematopoietic Growth Factors: Erythropoietins

AE (4)

A

• Iron deficiency: If iron stores cannot keep up with
erythropoiesis, patients may develop a functional iron
deficiency. Patients need an iron supplement.
When you make RBC it has hemoglobin which needs iron - will take plasma iron

• Thrombosis: particularly in patients on dialysis. It is
recommended that these patients receive anticoagulant therapy as a prophylactic measure.
• Hypertension: Although increased hematocrit can lead to increased blood pressure, the mechanism is believed to be more likely a result of the interaction between erythropoietin and vasoactive factors such as angiotensin II.
• Seizures: Seizures have been reported in dialysis patients receiving epoetin alfa

29
Q

Hematopoietic Growth Factors: Colony Stimulating Factors

function?
2 prototypes

A

Colony-stimulating factors (CSFs) are agents that stimulate the production of neutrophils and monocytes
• Granulocyte Colony-Stimulating Factor (G-CSF):
filgrastim, lenograstim, pegfilgrastim
- astim

• Granulocyte-Monocyte Colony-Stimulating Factor (GMCSF): sargramostim
- ostim

30
Q

Hematopoietic Growth Factors: Colony Stimulating Factors

MOA?

A

• The CSFs work by binding to receptors on myeloid
progenitor cells. These are cells in the bone marrow that make RBCs, platelets, granulocytes, and monocytes. The actions of these receptors are mediated through the Janus protein kinase/signal transducers and activators of transcription (JAK/STAT) pathway.
• G-CSFs stimulate proliferation and differentiation only of progenitors commited to becoming neutrophils.
• GM-CSFs stimulate the production of neutrophils and
monocytes, as well as the actions (phagocytosis,
superoxide production, and cell-mediated toxicity) of
neutrophils, monocytes, and eosinophils

31
Q

Hematopoietic Growth Factors: Colony Stimulating Factors

Pharmacokinetics

A

• The elimination half-life of filgrastim is 3 to 5 hours and is fairly consistent between the IV and SC routes. It is largely cleared through renal excretion.
• The addition of a polyethylene glycol (PEG) to filgrastim produced pegfilgrastim, which because of its large size is not as readily cleared by the kidneys. Pegfilgrastim therefore has an extended
elimination half-life of about 40 hours, compared with filgrastim

32
Q

Hematopoietic Growth Factors: Colony Stimulating Factors

Indications

A

• Adjunct to myelosuppressive chemotherapy
• Severe chronic neutropenia
• Prevention and treatment of neutropenia in human
immunodeficiency virus (HIV) infection

33
Q

Hematopoietic Growth Factors: Colony Stimulating Factors

AE? (6)

A
  • Bone loss: G-CSF increases osteoclast activity, leading to bone resorption.
  • Joint pain: G-CSF appears to stimulate cytokine release, leading to joint pain.
  • Renal dysfunction: G-CSF causes a transient and reversible renal impairment, believed to be caused by leukostasis (clumping of leukocytes) in the kidneys.
  • Acute respiratory distress: G-CSF can lead to lung injury because of accumulation and activation of neutrophils in the lungs.
  • Splenomegaly or splenic rupture: Cases of splenic rupture have been reported with G-CSF. balloon like
  • Sickle cell crises: Sometimes fatal in patients with sickle cell disorders
34
Q

Hematopoietic Growth Factors: Megakaryocyte

(Thrombopoietic) Growth Factors

A

• Megakaryocyte (Thrombopoietic) Growth Factors
- Oprelvekin (IL-11)
- Thrombopoietin
• Oprelvekin (IL-11) and Thrombopoietin stimulate the growth of megakaryocytic progenitors and increase the number of peripheral platelets. They are used to treat thrombocytopenia following cancer chemotherapy.

  • Eltrombopag (oral) and romiplostim (injectable) are recently approved thrombopoietin agonists.
  • IL-11 treatment is associated with dizziness, headache and fatigue. Recombinant human trombopoietin is supposed to be better tolerated.